A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Chemotherapy
Related studies linked through entity extraction aliases.
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
- Status
- RECRUITING
- Phase
- PHASE2
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
- Status
- RECRUITING
- Phase
- PHASE3
Molecular Analysis and Treatment Options of Thymic Malignancies
- Status
- RECRUITING
- Phase
- N/A
PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients
- Status
- RECRUITING
- Phase
- NA
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
- Status
- RECRUITING
- Phase
- NA
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC
- Status
- RECRUITING
- Phase
- N/A
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
- Status
- WITHDRAWN
- Phase
- PHASE2
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
- Status
- WITHDRAWN
- Phase
- NA
ctDNA as a Biomarker for Treatment in Advanced NSCLC
- Status
- UNKNOWN
- Phase
- N/A
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2